RetatrutideCagriSemaSurvodutideMazdutideMax 4 peptides
Property
Categoryglp1glp1glp1glp1
Typepeptidepeptidepeptidepeptide
MechanismTriple agonist (GLP-1/GIP/Glucagon)Dual Semaglutide + Cagrilintide - GLP-1 + Amylin synergyDual GLP-1/Glucagon receptor agonistDual GLP-1/Glucagon receptor agonist
Research Stageresearchresearchresearchresearch
Dosing Range1-12mg weekly0.5-2.4mg weekly0.6-4.8mg weekly3-6mg weekly
FrequencyOnce weeklyOnce weeklyOnce weeklyOnce weekly
Half-Life~6 days~7 days~6-7 days~5-6 days
Bioavailability / Route
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Onset Time2-4 weeks2-4 weeks2-4 weeks2-4 weeks
Key Benefits
Weight managementMetabolic optimization
Weight managementMaximum weight lossMetabolic optimization
Weight managementMASH treatmentLiver health
Weight managementMASH/NAFLDMetabolic health
Key Risks
NauseaDiarrheaVomiting
NauseaVomitingDiarrheaConstipation
NauseaVomitingDiarrhea
NauseaDiarrheaDecreased appetite
StorageRefrigerated (2-8°C)Refrigerated (2-8°C)Refrigerated (2-8°C)Refrigerated (2-8°C)
Property comparison · Radar

Profile shape

Duration
Quick Onset
Versatility
Tolerability
Use Cases
Stackability
Typical dose ranges

Dose envelope

For educational purposes only. Consult a healthcare provider before starting any peptide protocol.